<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943159</url>
  </required_header>
  <id_info>
    <org_study_id>CUV100</org_study_id>
    <nct_id>NCT04943159</nct_id>
  </id_info>
  <brief_title>Afamelanotide in Patients Suffering With Acne Vulgaris</brief_title>
  <official_title>A Phase II, Randomised, Open Label Pilot Study to Evaluate the Efficacy and Safety of Two Dosage Regimens of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Mild to Moderate Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinuvel Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinuvel Pharmaceuticals Limited</source>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effect of afamelanotide on the facial inflammatory&#xD;
      acne-related lesions in patients with mild to moderate acne vulgaris, including tolerability&#xD;
      of afamelanotide by patients with moderate acne vulgaris and effects of the treatment on&#xD;
      quality of life in eligible patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2010</start_date>
  <completion_date type="Actual">March 8, 2011</completion_date>
  <primary_completion_date type="Actual">March 8, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change in Number of Facial Inflammatory Acne-related Lesions.</measure>
    <time_frame>From baseline to Day 56.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Afamelanotide group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Afamelanotide group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afamelanotide</intervention_name>
    <description>Group A is administered afamelanotide implant on Days 0, 21 and 42; Group B is administered afamelanotide implant on Days 0 and 28.</description>
    <arm_group_label>Afamelanotide group A</arm_group_label>
    <arm_group_label>Afamelanotide group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male subjects with a diagnosis of mild to moderate acne vulgaris, defined as an&#xD;
             Investigator's global assessment (IGA) score of 2-3;&#xD;
&#xD;
          -  Chronic course of acne vulgaris;&#xD;
&#xD;
          -  Acne-related lesions both on the face, chest and back;&#xD;
&#xD;
          -  Indication for treatment of acne vulgaris;&#xD;
&#xD;
          -  Aged 18-30 years (inclusive);&#xD;
&#xD;
          -  Fitzpatrick skin types I-III;&#xD;
&#xD;
          -  Providing written Informed Consent prior to the performance of any study-specific&#xD;
             procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects;&#xD;
&#xD;
          -  Diagnosis of severe acne vulgaris;&#xD;
&#xD;
          -  Allergy to afamelanotide or the polymer contained in the implant or to lidocaine or&#xD;
             other local anesthetic to be used during the administration of the implant;&#xD;
&#xD;
          -  Use of topical acne medication such as retinoids, benzoyl peroxide or topical&#xD;
             antibiotics within 2 weeks prior to the first dose;&#xD;
&#xD;
          -  Use of oral antibiotics for acne within 4 weeks prior to the first dose;&#xD;
&#xD;
          -  Use of topical corticosteroids on the face, chest and back or systemic corticosteroids&#xD;
             within the past 4 weeks prior to the first dose;&#xD;
&#xD;
          -  Use of systemic retinoids within 6 months prior to the first dose;&#xD;
&#xD;
          -  Use of anti-androgenic agents such as finasteride within 4 weeks prior to the first&#xD;
             dose;&#xD;
&#xD;
          -  Use of phototherapy devices for acne such as ClearLight™ or Zenozapper within 1 week&#xD;
             prior to the first dose;&#xD;
&#xD;
          -  Use of tanning booths or lamps within 1 week prior to the first dose;&#xD;
&#xD;
          -  Active skin disease that may interfere with evaluation;&#xD;
&#xD;
          -  Other forms of acne such as acne rosacea, acne excoriée, chloracne, acne conglobata,&#xD;
             acne fulminans, acne inversa or drug-induced acne;&#xD;
&#xD;
          -  Participation in a clinical trial for an investigational agent within 30 days prior to&#xD;
             the screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <results_first_submitted>August 13, 2021</results_first_submitted>
  <results_first_submitted_qc>September 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2021</results_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afamelanotide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A pooled analysis of all the patients treated by afamelanotide (group A and group B) was conducted as only 3 patients were recruited in the study (2 in group A and one in group B) due to difficulties in recruitment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Afamelanotide (Pooled Analysis)</title>
          <description>Group A are administered afamelanotide implant on Days 0, 21 and 42;&#xD;
Group B are administered afamelanotide implant on Days 0 and 28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A pooled analysis of all the patients treated by afamelanotide (group A and group B) was conducted as only 3 patients were recruited in the study (2 in group A and one in group B) due to difficulties in recruitment.</population>
      <group_list>
        <group group_id="B1">
          <title>Afamelanotide (Pooled Analysis)</title>
          <description>Group A are administered afamelanotide implant on Days 0, 21 and 42;&#xD;
Group B are administered afamelanotide implant on Days 0 and 28.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change in Number of Facial Inflammatory Acne-related Lesions.</title>
        <time_frame>From baseline to Day 56.</time_frame>
        <population>A pooled analysis of all the patients treated by afamelanotide (group A and group B) was conducted as only 3 patients were recruited in the study (2 in group A and one in group B) due to difficulties in recruitment.</population>
        <group_list>
          <group group_id="O1">
            <title>Afamelanotide (Pooled Analysis)</title>
            <description>Group A are administered afamelanotide implant on Days 0, 21 and 42;&#xD;
Group B are administered afamelanotide implant on Days 0 and 28.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Number of Facial Inflammatory Acne-related Lesions.</title>
          <population>A pooled analysis of all the patients treated by afamelanotide (group A and group B) was conducted as only 3 patients were recruited in the study (2 in group A and one in group B) due to difficulties in recruitment.</population>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>A pooled analysis of all the patients treated by afamelanotide (group A and group B) was conducted as only 3 patients were recruited in the study (2 in group A and one in group B) due to difficulties in recruitment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Afamelanotide (Pooled Analysis)</title>
          <description>Group A are administered afamelanotide implant on Days 0, 21 and 42;&#xD;
Group B are administered afamelanotide implant on Days 0 and 28.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Operations Manager</name_or_title>
      <organization>CLINUVEL PHARMACEUTICALS LTD</organization>
      <email>mail@clinuvel.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

